Dr. Andy Crew, Former CTO of Arvinas, Joins Our Scientific Advisory Board
“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
We are excited to announce that Dr. Andy Crew has joined General Proximity's Scientific Advisory Board. Dr. Crew is a seasoned expert in drug discovery with a strong focus on induced proximity. Previously, he served as Chief Technology Officer at Siduma Therapeutics and Arvinas.
At Siduma Therapeutics, Dr. Crew played a pivotal role in developing a novel class of induced proximity molecules targeting extracellular proteins. As the first employee and CTO at Arvinas, he led a groundbreaking team that successfully advanced the first PROTAC molecules into clinical development, overcoming significant industry skepticism regarding oral bioavailability and blood-brain barrier penetration.
With over 20 years of experience in traditional small molecule development, Dr. Crew has led multidisciplinary project teams at Astellas/OSI, delivering clinical candidates for oncology targeting mTORC1/2, PTK2, cKit, and KDR. His earlier work at Tularik in the UK focused on structure-based drug discovery for cardiovascular diseases and cancer.
Dr. Crew’s extensive expertise will be invaluable as we continue to advance our scientific initiatives at General Proximity. Please join us in welcoming him to the team!
